Market Access/ News/ News Nymox slumps as FDA rejects filing for prostate drug Phil Taylor benign prostatic hyperplasia, fexapotide, Nymox Pharma, regulatory 0 Comment Shares in US biotech Nymox Pharma have plunged after the company announced the FDA had refused to accept Share X Nymox slumps as FDA rejects filing for prostate drug https://pharmaphorum.com/news/nymox-slumps-as-fda-rejects-filing-for-prostate-drug/
benign prostatic hyperplasia, fexapotide, Nymox Pharma, regulatory
0 Comment
